706 related articles for article (PubMed ID: 10737486)
1. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM
J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
3. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
Noguchi M; Stamey TA; Neal JE; Yemoto CE
J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
6. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
7. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
[TBL] [Abstract][Full Text] [Related]
8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
9. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.
Salomon L; Anastasiadis AG; Johnson CW; McKiernan JM; Goluboff ET; Abbou CC; Olsson CA; Benson MC
Urology; 2003 Aug; 62(2):304-9. PubMed ID: 12893340
[TBL] [Abstract][Full Text] [Related]
10. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
11. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml or less.
Noldus J; Stamey TA
J Urol; 1996 Feb; 155(2):441-3. PubMed ID: 8558630
[TBL] [Abstract][Full Text] [Related]
12. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.
Stamey TA; Donaldson AN; Yemoto CE; McNeal JE; Sözen S; Gill H
J Urol; 1998 Dec; 160(6 Pt 2):2412-7. PubMed ID: 9817394
[TBL] [Abstract][Full Text] [Related]
13. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
14. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
[TBL] [Abstract][Full Text] [Related]
17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
18. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
[TBL] [Abstract][Full Text] [Related]
20. Biological determinants of cancer progression in men with prostate cancer.
Stamey TA; McNeal JE; Yemoto CM; Sigal BM; Johnstone IM
JAMA; 1999 Apr; 281(15):1395-400. PubMed ID: 10217055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
